

SMALL-CAP TRADE IDEA

NASDAQ: (\$RNTX)

“With \$106M in assets and no long-term debt, the company is financially positioned to advance multiple clinical milestones.”

Rein Therapeutics Inc. (NASDAQ: RNTX) is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing first-in-class therapies for orphan pulmonary and fibrosis indications. Formerly known as Aileron Therapeutics, the company rebranded in early 2025 to reflect its focused mission in treating life-threatening pulmonary conditions.

Technical Analysis

Short Term:

Rein Therapeutics, Inc. (RNTX), is facing a potential breakout zone targeting the \$3.53 level, which marks a prominent volume gap area. This gap indicates limited historical resistance, offering a technical opportunity for a swift price surge if buying momentum builds.


- **\$3.53 VOLUME GAP TARGET:** Thin volume between current levels and \$3.53 suggests price could rise quickly on increased demand.
- **VWAP AND PoC ALIGNMENT:** The price is hovering near key volume-weighted metrics, indicating equilibrium and a potential base for a move higher.
- **RECENT PRICE SPIKE ATTEMPT:** A fresh push with increased volume hints at renewed bullish interest and possible trend reversal.



Long Term:

Rein Therapeutics, Inc. (RNTX), the stock is now compressing within a clearly defined large wedge pattern, a setup that often precedes major price moves once a breakout occurs. The price action is tightening near the wedge's apex around \$1.89, signaling a potential breakout zone.

- **LARGE FALLING WEDGE PATTERN:** This is typically a bullish reversal setup, especially after a prolonged downtrend.
- **TIGHT PRICE COMPRESSION:** Suggests diminishing selling pressure and potential for a breakout on volume increase.
- **SUPPORTIVE VOLUME PROFILE:** Dense volume nodes at the current level may act as a launchpad if buyer interest increases.



Pipeline & Clinical Progress

Rein's lead candidate, LTI-03, is a novel synthetic peptide designed to enhance alveolar epithelial cell survival and inhibit profibrotic signaling. In May 2025, the company initiated the RENEW Phase 2 trial, enrolling up to 120 patients with idiopathic pulmonary fibrosis (IPF). This trial aims to assess the activity of inhaled dry powder LTI-03 across multiple biomarkers, measure lung function, and evaluate the potential for healthy tissue regeneration. Topline data from this trial are expected in the first half of 2026.

Additionally, Rein is advancing LTI-01, a proenzyme therapy that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in both the U.S. and E.U., as well as Fast Track Designation in the U.S.

Financial Snapshot

Rein Therapeutics' recent financial report highlights a stable foundation and strategic capital deployment focused on advancing its clinical pipeline. Despite being a clinical-stage biotech company, Rein maintains a strong balance sheet with \$106 million in total assets and no long-term debt, which gives it a clear runway to continue developing its two lead drug candidates, LTI-03 and LTI-01. The company's controlled cash burn and focus on high-value orphan indications also provide a favorable risk/reward profile as it moves closer to key clinical catalysts.

- **\$106 million in total assets** with no long-term debt, providing financial flexibility to fund trials.
- **Targeted R&D investment** into lead candidates LTI-03 and LTI-01 aimed at underserved pulmonary diseases.
- **Disciplined financial management**, keeping operations lean while driving forward high-potential assets.

Outlook

Rein Therapeutics is strategically positioned in the biotech sector, targeting diseases with significant unmet medical needs and limited treatment options. The initiation of the RENEW Phase 2 trial for LTI-03 marks a critical milestone, with the potential to deliver transformative therapies for patients with IPF. The company's strong financial position and focused pipeline underscore its commitment to advancing novel treatments in pulmonary and fibrotic diseases.

Communicated Disclaimer

This distribution was conducted on behalf of Rein Therapeutics Inc. (NASDAQ: RNTX) and was funded by Outside The Box Capital Inc. and/or affiliates after Penny Stock News was engaged by Outside The Box Capital Inc. to advertise for Rein Therapeutics Inc. (NASDAQ: RNTX).